These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35134781)

  • 1. ECONOMIC BURDEN OF MULTIPLE SCLEROSIS IN GEORGIA.
    Gugutsidze D; Gigineishvili D; Kiziria M; Vashadze T; Tsiskaridze A; Shakarishvili R
    Georgian Med News; 2022 Jan; (322):167-170. PubMed ID: 35134781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of multiple sclerosis in Slovakia - from 2015 to 2020.
    Babela R; Dugas J
    BMC Health Serv Res; 2022 Dec; 22(1):1467. PubMed ID: 36461018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of multiple sclerosis on Kuwait health care system.
    Alowayesh MS; Ahmed SF; Al-Hashel J; Alroughani R
    PLoS One; 2019; 14(5):e0216646. PubMed ID: 31086393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
    Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
    Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
    Hartung DM
    Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
    da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
    BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care.
    Okuda DT; Burgess KW; Cook K; McCreary M; Winkler MD; Moog TM
    Mult Scler Relat Disord; 2022 Jul; 63():103920. PubMed ID: 35661567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.
    Paz-Zulueta M; Parás-Bravo P; Cantarero-Prieto D; Blázquez-Fernández C; Oterino-Durán A
    Mult Scler Relat Disord; 2020 Aug; 43():102162. PubMed ID: 32442885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
    Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
    J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada.
    Piwko C; Desjardins OB; Bereza BG; Machado M; Jaszewski B; Freedman MS; Einarson TR; Iskedjian M
    Pain Res Manag; 2007; 12(4):259-65. PubMed ID: 18080044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
    Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
    J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
    Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D
    Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact on healthcare resource utilization of multiple sclerosis in Spain.
    Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
    BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
    Kotsopoulos N; Connolly MP; Dort T; Kavaliunas A
    J Med Econ; 2020 Aug; 23(8):831-837. PubMed ID: 32400258
    [No Abstract]   [Full Text] [Related]  

  • 19. Differentiating societal costs of disability worsening in multiple sclerosis.
    Ness NH; Schriefer D; Haase R; Ettle B; Cornelissen C; Ziemssen T
    J Neurol; 2020 Apr; 267(4):1035-1042. PubMed ID: 31848738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect economic consequences of multiple sclerosis in Ireland.
    Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
    Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.